From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
J Natl Compr Canc Netw. 2015 Mar;13(3):288-90. doi: 10.6004/jnccn.2015.0040.
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may continue to be androgen-dependent after progression on androgen deprivation, which is analogous to prostate cancer.
唾液腺癌（SDC）是一种罕见且侵袭性的唾液腺恶性肿瘤，其标准治疗方法的证据有限。已知 SDC 过度表达雄激素受体，仅有少数病例报告对雄激素阻断有反应。本报告介绍了一例 SDC 对多种雄激素阻断治疗有反应的病例，包括对阿比特龙（一种有效的前列腺癌 CYP17 抑制剂）的快速反应。该病例代表了 SDC 对阿比特龙有反应的首例发表报告，表明表达雄激素受体的 SDC 可能可以用多种雄激素阻断治疗，包括阿比特龙等新型药物。该病例提示 SDC 在雄激素剥夺治疗进展后可能仍然依赖于雄激素，这类似于前列腺癌。
